Skip to main
  1. Stocks
  2. Abeona Therapeutics
  3. Forecast
ABEO

Abeona Therapeutics (ABEO) Stock Forecast & Price Target

Abeona Therapeutics (ABEO) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Abeona Therapeutics is benefiting from early commercial traction in ZEVASKYN, with 15 patient treatments completed since launch, including six in the most recently completed quarter, and a broader QTC network now spanning eight sites that should expand geographic access and accelerate adoption. The New Technology Add-On Payment status effective October 1, 2026 is an important reimbursement catalyst that can improve hospital economics for eligible Medicare beneficiaries, while 3Q26 revenue of $13.5M and $134.9M in cash, cash equivalents and marketable securities support execution through to cash flow break-even. Beyond the launch, the ABO-801 acquisition and $30M private placement add a Phase 3-ready pipeline asset without upfront cash at closing, strengthening longer-term growth optionality.

Bears say

Abeona Therapeutics is facing a negative outlook because lower-than-expected near-term revenues and higher operating expenses are pressuring the model, while reimbursement risk remains elevated for one of the most expensive classes of medicine. Its pipeline also carries substantial clinical and regulatory uncertainty, with prior Phase 3 setbacks that missed both co-primary symptom endpoints and a new program that sits in a “show me” category with high trial risk. Even with management’s assurances that the added pipeline asset will not divert resources from ZEVASKYN, the company is taking on an entirely new, higher-risk therapeutic vertical amid manufacturing and payor resistance concerns.

Abeona Therapeutics (ABEO) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Abeona Therapeutics (ABEO) Analyst Forecast & Price Prediction

Get the latest Abeona Therapeutics (ABEO) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Abeona Therapeutics (ABEO)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abeona Therapeutics (ABEO) Forecast

Analysts have given Abeona Therapeutics (ABEO) a Buy based on their latest research and market trends.

According to 4 analysts, Abeona Therapeutics (ABEO) has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abeona Therapeutics (ABEO)


Abeona Therapeutics (ABEO) Analyst Forecast & Price Prediction

Get the latest Abeona Therapeutics (ABEO) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Abeona Therapeutics (ABEO)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ABEO stock data and trends